Category Archives: Stem Cell Research

TORONTO, ONTARIO--(Marketwire - Feb 20, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Corporation") a life sciences company developing stem cell-related technologies, today announced a joint-venture agreement with ReNeu Inc. of Calgary, AB, Canada, ("ReNeu") and NexGen Medical Systems, Inc. of Melbourne, FL, USA ("NexGen"). ReNeu is a company formed to commercialize drug-based therapies to treat central nervous system disorders in combination with devices and processes for direct-to-brain administration. Subject to the definitive agreement, SCT and NexGen will license their respective technologies to ReNeu under world-wide,royalty-free licenses for the use of NexGen''s FDA-cleared EViTAR line of proprietary intracranial delivery systems and SCT''s NTx-265, -428 and -488 covering the proprietary use of drugs for the regeneration of endogenous neural stem cells. To the knowledge of the Corporation the EViTAR intracranial delivery system is the only FDA-cleared Class II medical device currently indicated for the injection of material into the brain during intracranial procedures. It is designed for site-specific, low-volume, high-concentration delivery of drugs to target tissues in the brain of patients suffering from stroke, neurodegenerative disease, and tumors. SCT''s NTx-265 is a therapeutic regimen of approved and clinically well-defined drugs that include human Chorionic Gonadotropin ("hCG") and erythropoietin … Continue reading →

AUGUSTA, Ga. -- There's been a lot of talk about stem cell research over the years. At GRU, there's a research trial using banked stem cells from umbilical cords saved at birth. One family, who banked their son's cord blood when he was born, hopes this investment in science pays off. Andrew Kijek is just one out of many who will be participating in a stem cell trial at Georgia regents University. "He's super smart, super fun and adventurous," said Maureen Kijek about her son, Andrew. If you ask 11-year old Andrew Kijek's mom, she'll tell you her son is a pretty cool kid. To use her words, she says he's just trapped in a body that doesn't work. "Things that he tries to do like grab at things or feed himself. His brain isn't telling his muscles the right thing. He doesn't have control over anything functional," said Kijek. Andrew was diagnosed with Cerebral palsy following a difficult child birth. Fast forward and his family has travelled from Michigan to, the Children's Hospital of Georgia. Andrew is being infused with his own umbilical cord blood stem cells as part of a trial to help improve his condition. "I decided … Continue reading →

Summit4StemCell Research Sherrie Gould, NP, describes the non-embryonic stem cell research underway at the Scripps Research Institute. By: Jeff Seckendorf … Continue reading →

Westminster Faith Debate: Stem cell research, abortion and the'soul of the embryo'? A significant number of people believe that human life begins at conception, but this does not necessarily mean they are opposed to abortion. The first debate in the 2013 series was chaired by Prof Linda Woodhead with a panel including Prof John Harris, Revd Dr Gerard Hughes, Dr David Albert Jones and Dr Abdul Majid Katme. Listen to podcasts of the presentations, responses and discussion from this first debate and view texts of the academic presentations here: http://www.religionandsociety.org.uk By: lancasteruniversity … Continue reading →

Faith Debate Highlights: Stem cell research, abortion and the'soul of the embryo'? Highlights from the first 2013 Westminster Faith Debate: Stem cell research, abortion and the'soul of the embryo'? http://www.religionandsociety.org.uk By: lancasteruniversity … Continue reading →

NEW YORK, Feb. 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Regenerative medicine and Stem cells Partnering Terms and Agreements http://www.reportlinker.com/p01098514/Regenerative-medicine-and-Stem-cells-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in regenerative medicine and stem cells deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for regenerative medicine and stem cells The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process … Continue reading →

TORONTO, ONTARIO--(Marketwire - Feb. 19, 2013) - NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) a life sciences company developing stem cell-related technologies, today announced that it is initiating a marketed offering of units, each unit will be comprised of a common share and common share purchase warrants in a proportion to be determined. The offering is to be effected in each of the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia by way of a prospectus supplement to SCT's base shelf prospectus of March 1, 2011. The number of units to be distributed, the price of each unit and the exercise price of each whole common share purchase warrant will be determined in context of the market with final terms to be determined at the time of pricing. Euro Pacific Canada Inc.is acting as theagent for the offering. The purpose of the offering is to provide the resources necessary to conclude the merger of Trillium Therapeutics Inc. into SCT announced February 4th, 2013 and to permit the exercise of the option by SCT to acquire the license to the Tigecycline Intellectual Property from … Continue reading →

RBC Life - Stem-Kine Gives More Energy Visit RBC Life: http://www.rbclife.com Follow us on Twitter http://www.twitter.com Like us on Facebook: http://www.facebook.com Key Benefits: Supports the body's rejuvenation system* Nutritionally supports bone marrow and the body's natural stem cell functions* What is it? Stem-Kine is a unique supplement made with all natural ingredients and vitamin D through a proprietary fermentation process. This product nourishes the bone marrow supporting your body's natural processes for producing and increasing levels of circulating stem cells.* Shown in published clinical studies to provide ideal nutrition to the bone marrow, enabling it to increase its production of stem cells, the body's system for the renewal of diseased and damaged tissues. What is it formulated to do? Stem-Kine has been formulated by an expert in the field of stem cell research to nutritionally support the metabolism of bone marrow enabling it to enhance production of stem cells. By doing so, your body will have a greater ability to restore and rejuvenate itself.* Who may benefit? Anyone can benefit from supporting the body's processes for increasing the number of circulating stem cells, particularly those over the age of 25.* How is it used? Stem-Kine … Continue reading →

Melbourne, Feb. 18 (ANI): A team of scientists from Australia are turning human skin cells into eye cells by using stem cell research to find a way to treat a common but incurable form of blindness. According to figures, age-related macular degeneration that results from dying retinal cells, affects one in seven older Australians and costs the 5.15 billion dollars a year. The team at Melbourne's Centre for Eye Research Australia (CERA) takes skin cells from affected patients, turns them into stem cells and then into new retinal cells, Herald Sun reported. These cells are then compared with the patient's damaged cells, allowing them to see in detail what's gone wrong. A new charity, the National Stem Cell Foundation of Australia, has devoted its first investment to the project, bringing Kathryn Davidson, a US stem cell expert, to the centre from Seattle. Davidson said that stem cell research has lets her team "mimic the disease in a dish," with a view to finding means for better diagnosis and treatment. (ANI) Continued here: Skin cells 'key to beating blindness' … Continue reading →

Scientists are turning human skin cells into eye cells by using stem cell research, with their sights set on unravelling a common but incurable form of blindness. Age-related macular degeneration, which results from dying retinal cells, affects one in seven older Australians and costs the country's economy $5.15 billion a year, figures show. But little is understood about how or why it occurs. Enter a team at Melbourne's Centre for Eye Research Australia (CERA), which is taking skin cells from affected patients, turning them into stem cells and then into new retinal cells. These are then compared with the patient's damaged cells, allowing the researchers to see in detail what's gone wrong. A new charity, the National Stem Cell Foundation of Australia, has devoted its first investment to the project, bringing Kathryn Davidson, a US stem cell expert, to the centre from Seattle. 'We know (with macular degeneration) that certain cells in the retina die, and so do the other cells that depend on them, but we need to know how and why,' Dr Davidson told those gathered at the charity's launch in Melbourne on Monday. Dr Davidson said stem cell research lets her team 'mimic the disease in a … Continue reading →